HOME >> MEDICINE >> NEWS
Heart-stopping drugs

A NEW way of stopping the heart during bypass operations could reduce damage to the heart and improve patients' chances of a full recovery.

More than a million people a year have open-heart surgery to unblockor bypass clogged arteries, or repair damaged valves. The heart is usually stopped for about one hour while they are under the knife because it is impossible to operate on a moving target. But the standard method of achieving this- flooding the heart with potassium ions- can cause permanent damage.

Now Geoffrey Dobson and Michael Jones of James Cook University in Townsville, Australia, have developed an alternative. It has only been tested on animals so far, but experts say the results, due to appear in the Journal of Thoracic and Cardiovascular Surgery, look promising. "By keeping potassium levels normal they are preventing injuries to the muscle cells and to the vessels that carry blood to the heart," says Peter Macdonald, a cardiologist at St Vincent's Hospital in Sydney.

In resting muscle cells, the distribution of ions across the cell membrane generates an electric potential. The waves of electrical activity that sweep across the heart, telling muscle cells to contract, are generated when channels in the membrane open, allowing ions to flow across the membrane and depolarise the cells. Flooding the heart with potassium ions freezes its cells in this depolarised state.

Dobson and Jones instead freeze the heart in the resting state using two drugs: adenosine, which opens some of the channels that transport potassium ions in and out of the cell, and lignocaine (known as lidocainein the US), which blocks sodium ion channels.

"There are two ways to stop a heart cell. Let it run out of gas- that's the potassium infusion-or to not even turn it on. That's what Dobson has done," says Jakob Vinten-Johansen, a cardiovascular physiologist at Emory University in Atlanta, Georgia, who now collaborates with Dobson.

Whe
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
17-Sep-2003


Page: 1 2 3

Related medicine news :

1. UW research shows risk factors for relapse among health care professionals who abuse drugs
2. New studies show mixed results on epilepsy drugs and birth defects
3. Newly discovered pathway might help in design of cancer drugs
4. Study examines consequences of Thailands war on drugs
5. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
6. Three anti-platelet drugs used in combination are safe
7. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
8. Clot-busting drugs may help detect potentially deadly leg clots
9. Herb used to treat diabetes works like modern-day prescription drugs, study suggests
10. Penn study shows how next-generation diabetic drugs could work more selectively
11. Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: